Boston Therapeutics, Inc. (BTHE) is a pharmaceutical company focused on the development, manufacturing and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs. The company’s current product pipeline, PAZ320 and IPOXYN™, is comprised of therapies developed to treat patient populations with Type 2 diabetes.